Differential methylation may lead to different polyadenylation (as described in mice51) and hence varying transcripts, yet we found differential expression of all exons in HM13. Our methodology also did not allow to exclude promoter switching from an imprinted promoter to a non-imprinted one, as already described for IGF2 and MEST27,36, as cause of HM13 LOI in cancer. The gene discussed is IGF2; the disease is cancer.